Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical intervention
|
| gptkbp:controversy |
concerns about study methodology
limited peer-reviewed evidence |
| gptkbp:countryOfOperation |
gptkb:Brazil
gptkb:China |
| https://www.w3.org/2000/01/rdf-schema#label |
Proxalutamide for COVID-19
|
| gptkbp:proposedEffect |
reduce mortality
reduce hospitalization reduce severity of COVID-19 |
| gptkbp:proposedMechanism |
androgen receptor antagonism
|
| gptkbp:regulates |
not approved for COVID-19 treatment by major health authorities
|
| gptkbp:studiedIn |
clinical trials
|
| gptkbp:treatment |
gptkb:COVID-19
|
| gptkbp:uses |
proxalutamide
|
| gptkbp:bfsParent |
gptkb:Kintor_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|